Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study

E. Hamilton, W. Davis, D. Bruce, T. Davis
{"title":"Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study","authors":"E. Hamilton, W. Davis, D. Bruce, T. Davis","doi":"10.1210/jc.2016-3570","DOIUrl":null,"url":null,"abstract":"Context: Studies of hip fracture complicating diabetes have not considered the effect of premature mortality. Objective: The aim of our study was to determine influence of the competing risk of death on the association between type 2 diabetes and hip fracture. Design: The study was designed as a longitudinal observational study. Setting: The study setting was an urban community. Patients: Participants included 1291 patients with type 2 diabetes (mean age 64.0 years) and 5159 matched residents without diabetes. Main Outcome Measures: Primary outcome measures were incident hip fracture hospitalizations and deaths. Hip fracture risk was assessed using proportional hazards and competing risk regression modeling. Results: During a mean of 14.1 years of follow-up, the incidence rate ratio for first hip fracture hospitalization in participants with vs without diabetes was 1.33 [95% confidence interval (CI), 1.05 to 1.68; P = 0.013]. Type 2 diabetes was associated with a cause-specific hazard ratio (csHR) for hip fracture of 1.50 (95% CI, 1.19 to 1.89; P < 0.001) and a subdistribution hazard ratio (sdHR) of 1.21 (95% CI, 0.96 to 1.52; P = 0.11) after adjustment for age, sex, and comorbidities. In patients with diabetes, significant csHRs for incident hip fracture were male sex (protective), body mass index (protective), insulin use, and renal impairment. These variables, with increasing age, also had significant sdHRs. Conclusions: The diabetes-associated risk of hip fracture is attenuated after allowing for the competing risk of death. Risk factors for hip fracture in diabetes were those in reported in general population studies plus insulin use.","PeriodicalId":22632,"journal":{"name":"The Journal of Clinical Endocrinology & Metabolism","volume":"137 1","pages":"551–559"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jc.2016-3570","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Context: Studies of hip fracture complicating diabetes have not considered the effect of premature mortality. Objective: The aim of our study was to determine influence of the competing risk of death on the association between type 2 diabetes and hip fracture. Design: The study was designed as a longitudinal observational study. Setting: The study setting was an urban community. Patients: Participants included 1291 patients with type 2 diabetes (mean age 64.0 years) and 5159 matched residents without diabetes. Main Outcome Measures: Primary outcome measures were incident hip fracture hospitalizations and deaths. Hip fracture risk was assessed using proportional hazards and competing risk regression modeling. Results: During a mean of 14.1 years of follow-up, the incidence rate ratio for first hip fracture hospitalization in participants with vs without diabetes was 1.33 [95% confidence interval (CI), 1.05 to 1.68; P = 0.013]. Type 2 diabetes was associated with a cause-specific hazard ratio (csHR) for hip fracture of 1.50 (95% CI, 1.19 to 1.89; P < 0.001) and a subdistribution hazard ratio (sdHR) of 1.21 (95% CI, 0.96 to 1.52; P = 0.11) after adjustment for age, sex, and comorbidities. In patients with diabetes, significant csHRs for incident hip fracture were male sex (protective), body mass index (protective), insulin use, and renal impairment. These variables, with increasing age, also had significant sdHRs. Conclusions: The diabetes-associated risk of hip fracture is attenuated after allowing for the competing risk of death. Risk factors for hip fracture in diabetes were those in reported in general population studies plus insulin use.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
过早死亡对2型糖尿病和髋部骨折之间关系的影响:Fremantle糖尿病研究
背景:髋部骨折合并糖尿病的研究未考虑过早死亡的影响。目的:我们研究的目的是确定竞争死亡风险对2型糖尿病和髋部骨折相关性的影响。设计:本研究设计为纵向观察性研究。环境:研究环境为城市社区。患者:参与者包括1291例2型糖尿病患者(平均年龄64.0岁)和5159名匹配的无糖尿病居民。主要结局指标:主要结局指标为髋部骨折住院和死亡。采用比例风险和竞争风险回归模型评估髋部骨折风险。结果:在平均14.1年的随访期间,糖尿病患者与非糖尿病患者首次髋部骨折住院的发生率比为1.33[95%可信区间(CI), 1.05至1.68;P = 0.013]。2型糖尿病与髋部骨折的病因特异性危险比(csHR)相关,为1.50 (95% CI, 1.19至1.89;P < 0.001),亚分布风险比(sdHR)为1.21 (95% CI, 0.96 ~ 1.52;P = 0.11),校正了年龄、性别和合并症。在糖尿病患者中,男性(保护性)、体重指数(保护性)、胰岛素使用和肾功能损害是髋部骨折的显著csHRs。随着年龄的增长,这些变量也具有显著的sdhr。结论:考虑到死亡的竞争风险后,糖尿病相关的髋部骨折风险减弱。糖尿病髋部骨折的危险因素是在一般人群研究加上胰岛素使用中报道的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Treatment Preferences in Patients with Hypothyroidism: an Analysis of Eleven Randomized Controlled Trials. Metabolomics: A Promising Tool in the Prevention, Diagnosis, and Treatment of Obesity. Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension. The changing treatment paradigm in prolactinoma - a prospective series of 100 consecutive neurosurgical cases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1